The Risky Reliance on Small Surrogate End Point Studies When Planning a Large Prevention Trial
The Risky Reliance on Small Surrogate End Point Studies When Planning a Large Prevention Trial
Summary The definitive evaluation of treatment to prevent a chronic disease with low incidence in middle age, such as cancer or cardiovascular disease, requires a trial with a large sample size of perhaps 20000 or more. To help to decide whether to implement a large true end point trial, investigators …